Nan Fung Group Holdings Ltd
Long book
$121.3M
Q1 2026
Positions
24
Top-10 weight
83%
concentration
Last quarter
+7.6%
SPY +14.8%
Turnover
24%
of book per quarter
Strategy in plain words
auto-generated from filingsNan Fung Group Holdings Ltd is a concentrated fundamental stock-picker, specialised in healthcare (96% of the long book), running a $121.3M US long book across 24 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. Turnover is modest: positions are typically held for years. Current anchor positions: EVOMMUNE INC, MAPLIGHT THERAPEUTICS INC, LB PHARMACEUTICALS INC, OCULIS HOLDING AG, INCYTE CORP.
Over the last 9 quarters its long book ran on average 1.1pp per quarter behind the S&P 500, beating the index in 3 of 9 quarters. We rate its filings highest-signal: new buys here are worth attention.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-10.3%
Q2 2024
+15.1%
Q3 2024
-1.8%
Q4 2024
-10.6%
Q1 2025
+3.2%
Q2 2025
+7.5%
Q3 2025
+12.7%
Q4 2025
+7.2%
Q1 2026
+7.6%
Sector allocation
Healthcare 97%
Technology 3%
Long book by quarter
What does Nan Fung own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| EVMN EVOMMUNE INC | Healthcare | 1.4M | $33.1M | 27.3% | Held |
| MPLT MAPLIGHT THERAPEUTICS INC | Healthcare | 971.3K | $19.7M | 16.3% | Held |
| LBRX LB PHARMACEUTICALS INC | Healthcare | 630.7K | $15.6M | 12.8% | +110.2% |
| OCS OCULIS HOLDING AG | Healthcare | 350.7K | $9.3M | 7.7% | -31.9% |
| INCY INCYTE CORP | Healthcare | 53.7K | $5.1M | 4.2% | -8.9% |
| RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 49.1K | $4.3M | 3.5% | Held |
| CELC CELCUITY INC | Healthcare | 28.3K | $3.2M | 2.7% | New |
| PCOR PROCORE TECHNOLOGIES INC | Technology | 53.3K | $3.0M | 2.5% | Held |
| MDGL MADRIGAL PHARMACEUTICALS INC | Healthcare | 5.7K | $3.0M | 2.4% | -52.2% |
| KYMR KYMERA THERAPEUTICS INC | Healthcare | 30.9K | $2.6M | 2.1% | Held |
| ACAD ACADIA PHARMACEUTICALS INC | Healthcare | 103.0K | $2.3M | 1.9% | Held |
| HELP CYBIN INC | Healthcare | 460.0K | $2.2M | 1.8% | Held |
| RVMD REVOLUTION MEDICINES INC | Healthcare | 19.3K | $1.9M | 1.5% | Held |
| RXRX RECURSION PHARMACEUTICALS-A | Healthcare | 595.3K | $1.8M | 1.5% | Held |
| INSM INSMED INC | Healthcare | 6.6K | $1.1M | 0.9% | New |
| HRMY HARMONY BIOSCIENCES HOLDINGS | Healthcare | 27.0K | $758K | 0.6% | Held |
| TRDA ENTRADA THERAPEUTICS INC | Healthcare | 49.1K | $619K | 0.5% | Held |
| RANI RANI THERAPEUTICS HOLDINGS-A | Healthcare | 493.6K | $363K | 0.3% | Held |
| BOLT BOLT BIOTHERAPEUTICS INC | Healthcare | 29.3K | $118K | 0.1% | -49.9% |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 14, 2026 | 24 | $121.3M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 13, 2026 | 27 | $111.7M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 13, 2025 | 24 | $59.6M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 13, 2025 | 20 | $63.4M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 14, 2025 | 35 | $122.6M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 13, 2025 | 35 | $116.9M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 13, 2024 | 38 | $116.1M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 13, 2024 | 44 | $93.7M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 14, 2024 | 45 | $107.9M | canonical | SEC ↗ |